Unraveling Self-Reported Signs of Central Sensitization in Breast Cancer Survivors with Upper Limb Pain: Prevalence Rate and Contributing Factors

Hypersensitivity of the central nervous system to environmental and chemical stimuli is a clinical feature of central sensitization mechanisms that can be assessed with the central sensitization inventory (CSI). The aim was to determine prevalence rate of this feature and explore the treatment-, pat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pain physician 2018-05, Vol.21 (3), p.E247-E256
Hauptverfasser: De Groef, An, Meeus, Mira, De Vrieze, Tessa, Vos, Lore, Van Kampen, Marijke, Geraerts, Inge, Devoogdt, Nele
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page E256
container_issue 3
container_start_page E247
container_title Pain physician
container_volume 21
creator De Groef, An
Meeus, Mira
De Vrieze, Tessa
Vos, Lore
Van Kampen, Marijke
Geraerts, Inge
Devoogdt, Nele
description Hypersensitivity of the central nervous system to environmental and chemical stimuli is a clinical feature of central sensitization mechanisms that can be assessed with the central sensitization inventory (CSI). The aim was to determine prevalence rate of this feature and explore the treatment-, patient-, pain-, and psychosocial-related variables associated with the degree of self-reported signs of central sensitization, assessed with the CSI (0-100), in breast cancer survivors at long-term. Cross-sectional study. University Hospitals, Leuven, Belgium. One hundred and forty-six women with persistent pain, more than one year after breast cancer surgery, were included. The following factors were analyzed by bivariable and multivariable analysis: 1) treatment-related variables (type of surgery, levels of lymph node dissected, radiotherapy, chemotherapy, hormone therapy, and trastuzumab); 2) patient's related variables (age and body mass index); 3) pain-related variables (pain intensity, pain quality, primary hyperalgesia, and index of widespread pain); and 4) psychosocial variables (the degree of pain catastrophizing and vigilance and awareness to pain). The dependent variable was degree of central sensitization measured with the CSI. Additionally, a stepwise regression was performed. Fifty-five (38%) patients reported signs of central sensitization measured with the CSI (i.e., > 40/100). From multivariable analysis, it appears that more severe pain quality and higher levels of pain catastrophizing contribute to a higher degree of central sensitization. The stepwise regression revealed that up to 24% of variance of the CSI can be explained by these factors. A selection bias may be present since patients were all recruited from a larger cohort participating in clinical trials on the effectiveness of physical therapy after breast cancer treatment. Signs of central sensitization cannot be neglected in breast cancer survivors at long term. More severe pain quality and pain catastrophizing contribute to higher levels of central sensitization in this population. Breast neoplasm, pain, central sensitization mechanisms, central sensitization inventory.
doi_str_mv 10.36076/ppj.2018.3.e247
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2051069640</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2656012850</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-9f7e621e0e0c0effe3bb03831b2d30fc98e66c3dbd5b0b94ef6d2bc6ff87130b3</originalsourceid><addsrcrecordid>eNpdkcFuEzEURS0EomlhzwpZYsNmwrOdcWbY0VELSJGoGrK27Jnn4mhiD7YnCP6if4xDCwtWluxzr9_TIeQVg6WQsJbvpmm_5MCapVgiX62fkAVnNVSMrdqnZMFqISrB6vaMnKe0BxCybcVzcsbbZs1EAwtyv_NRH3F0_o5ucbTVLU4hZhzo1t35RIOlHfoc9ViefXLZ_dLZBU-dp5cRdcq0077HSLdzPLpjiIn-cPkb3U1Tudy4g6E32vn39CbiUY9YWHqrM1LtB9qFUu3MnE_fX-s-l_gL8szqMeHLx_OC7K6vvnafqs2Xj5-7D5uqL1vkqrVrlJwhIPSA1qIwBkQjmOGDANu3DUrZi8EMtQHTrtDKgZteWntaHYy4IG8feqcYvs-Ysjq41OM4ao9hTopDzUC2cgUFffMfug9z9GU6xWUtgfGmPlHwQPUxpBTRqim6g44_FQP1R5cqutRJlxLqqugqkdePxbM54PAv8NeP-A0UhJOD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2656012850</pqid></control><display><type>article</type><title>Unraveling Self-Reported Signs of Central Sensitization in Breast Cancer Survivors with Upper Limb Pain: Prevalence Rate and Contributing Factors</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>De Groef, An ; Meeus, Mira ; De Vrieze, Tessa ; Vos, Lore ; Van Kampen, Marijke ; Geraerts, Inge ; Devoogdt, Nele</creator><creatorcontrib>De Groef, An ; Meeus, Mira ; De Vrieze, Tessa ; Vos, Lore ; Van Kampen, Marijke ; Geraerts, Inge ; Devoogdt, Nele</creatorcontrib><description>Hypersensitivity of the central nervous system to environmental and chemical stimuli is a clinical feature of central sensitization mechanisms that can be assessed with the central sensitization inventory (CSI). The aim was to determine prevalence rate of this feature and explore the treatment-, patient-, pain-, and psychosocial-related variables associated with the degree of self-reported signs of central sensitization, assessed with the CSI (0-100), in breast cancer survivors at long-term. Cross-sectional study. University Hospitals, Leuven, Belgium. One hundred and forty-six women with persistent pain, more than one year after breast cancer surgery, were included. The following factors were analyzed by bivariable and multivariable analysis: 1) treatment-related variables (type of surgery, levels of lymph node dissected, radiotherapy, chemotherapy, hormone therapy, and trastuzumab); 2) patient's related variables (age and body mass index); 3) pain-related variables (pain intensity, pain quality, primary hyperalgesia, and index of widespread pain); and 4) psychosocial variables (the degree of pain catastrophizing and vigilance and awareness to pain). The dependent variable was degree of central sensitization measured with the CSI. Additionally, a stepwise regression was performed. Fifty-five (38%) patients reported signs of central sensitization measured with the CSI (i.e., &gt; 40/100). From multivariable analysis, it appears that more severe pain quality and higher levels of pain catastrophizing contribute to a higher degree of central sensitization. The stepwise regression revealed that up to 24% of variance of the CSI can be explained by these factors. A selection bias may be present since patients were all recruited from a larger cohort participating in clinical trials on the effectiveness of physical therapy after breast cancer treatment. Signs of central sensitization cannot be neglected in breast cancer survivors at long term. More severe pain quality and pain catastrophizing contribute to higher levels of central sensitization in this population. Breast neoplasm, pain, central sensitization mechanisms, central sensitization inventory.</description><identifier>ISSN: 1533-3159</identifier><identifier>EISSN: 2150-1149</identifier><identifier>DOI: 10.36076/ppj.2018.3.e247</identifier><identifier>PMID: 29871380</identifier><language>eng</language><publisher>United States: American Society of Interventional Pain Physician</publisher><subject>Breast cancer ; Cancer therapies ; Hyperalgesia ; Monoclonal antibodies ; Pain ; Targeted cancer therapy ; Variables</subject><ispartof>Pain physician, 2018-05, Vol.21 (3), p.E247-E256</ispartof><rights>2018. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-9f7e621e0e0c0effe3bb03831b2d30fc98e66c3dbd5b0b94ef6d2bc6ff87130b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29871380$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>De Groef, An</creatorcontrib><creatorcontrib>Meeus, Mira</creatorcontrib><creatorcontrib>De Vrieze, Tessa</creatorcontrib><creatorcontrib>Vos, Lore</creatorcontrib><creatorcontrib>Van Kampen, Marijke</creatorcontrib><creatorcontrib>Geraerts, Inge</creatorcontrib><creatorcontrib>Devoogdt, Nele</creatorcontrib><title>Unraveling Self-Reported Signs of Central Sensitization in Breast Cancer Survivors with Upper Limb Pain: Prevalence Rate and Contributing Factors</title><title>Pain physician</title><addtitle>Pain Physician</addtitle><description>Hypersensitivity of the central nervous system to environmental and chemical stimuli is a clinical feature of central sensitization mechanisms that can be assessed with the central sensitization inventory (CSI). The aim was to determine prevalence rate of this feature and explore the treatment-, patient-, pain-, and psychosocial-related variables associated with the degree of self-reported signs of central sensitization, assessed with the CSI (0-100), in breast cancer survivors at long-term. Cross-sectional study. University Hospitals, Leuven, Belgium. One hundred and forty-six women with persistent pain, more than one year after breast cancer surgery, were included. The following factors were analyzed by bivariable and multivariable analysis: 1) treatment-related variables (type of surgery, levels of lymph node dissected, radiotherapy, chemotherapy, hormone therapy, and trastuzumab); 2) patient's related variables (age and body mass index); 3) pain-related variables (pain intensity, pain quality, primary hyperalgesia, and index of widespread pain); and 4) psychosocial variables (the degree of pain catastrophizing and vigilance and awareness to pain). The dependent variable was degree of central sensitization measured with the CSI. Additionally, a stepwise regression was performed. Fifty-five (38%) patients reported signs of central sensitization measured with the CSI (i.e., &gt; 40/100). From multivariable analysis, it appears that more severe pain quality and higher levels of pain catastrophizing contribute to a higher degree of central sensitization. The stepwise regression revealed that up to 24% of variance of the CSI can be explained by these factors. A selection bias may be present since patients were all recruited from a larger cohort participating in clinical trials on the effectiveness of physical therapy after breast cancer treatment. Signs of central sensitization cannot be neglected in breast cancer survivors at long term. More severe pain quality and pain catastrophizing contribute to higher levels of central sensitization in this population. Breast neoplasm, pain, central sensitization mechanisms, central sensitization inventory.</description><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Hyperalgesia</subject><subject>Monoclonal antibodies</subject><subject>Pain</subject><subject>Targeted cancer therapy</subject><subject>Variables</subject><issn>1533-3159</issn><issn>2150-1149</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkcFuEzEURS0EomlhzwpZYsNmwrOdcWbY0VELSJGoGrK27Jnn4mhiD7YnCP6if4xDCwtWluxzr9_TIeQVg6WQsJbvpmm_5MCapVgiX62fkAVnNVSMrdqnZMFqISrB6vaMnKe0BxCybcVzcsbbZs1EAwtyv_NRH3F0_o5ucbTVLU4hZhzo1t35RIOlHfoc9ViefXLZ_dLZBU-dp5cRdcq0077HSLdzPLpjiIn-cPkb3U1Tudy4g6E32vn39CbiUY9YWHqrM1LtB9qFUu3MnE_fX-s-l_gL8szqMeHLx_OC7K6vvnafqs2Xj5-7D5uqL1vkqrVrlJwhIPSA1qIwBkQjmOGDANu3DUrZi8EMtQHTrtDKgZteWntaHYy4IG8feqcYvs-Ysjq41OM4ao9hTopDzUC2cgUFffMfug9z9GU6xWUtgfGmPlHwQPUxpBTRqim6g44_FQP1R5cqutRJlxLqqugqkdePxbM54PAv8NeP-A0UhJOD</recordid><startdate>20180501</startdate><enddate>20180501</enddate><creator>De Groef, An</creator><creator>Meeus, Mira</creator><creator>De Vrieze, Tessa</creator><creator>Vos, Lore</creator><creator>Van Kampen, Marijke</creator><creator>Geraerts, Inge</creator><creator>Devoogdt, Nele</creator><general>American Society of Interventional Pain Physician</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20180501</creationdate><title>Unraveling Self-Reported Signs of Central Sensitization in Breast Cancer Survivors with Upper Limb Pain: Prevalence Rate and Contributing Factors</title><author>De Groef, An ; Meeus, Mira ; De Vrieze, Tessa ; Vos, Lore ; Van Kampen, Marijke ; Geraerts, Inge ; Devoogdt, Nele</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-9f7e621e0e0c0effe3bb03831b2d30fc98e66c3dbd5b0b94ef6d2bc6ff87130b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Hyperalgesia</topic><topic>Monoclonal antibodies</topic><topic>Pain</topic><topic>Targeted cancer therapy</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>De Groef, An</creatorcontrib><creatorcontrib>Meeus, Mira</creatorcontrib><creatorcontrib>De Vrieze, Tessa</creatorcontrib><creatorcontrib>Vos, Lore</creatorcontrib><creatorcontrib>Van Kampen, Marijke</creatorcontrib><creatorcontrib>Geraerts, Inge</creatorcontrib><creatorcontrib>Devoogdt, Nele</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Pain physician</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>De Groef, An</au><au>Meeus, Mira</au><au>De Vrieze, Tessa</au><au>Vos, Lore</au><au>Van Kampen, Marijke</au><au>Geraerts, Inge</au><au>Devoogdt, Nele</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Unraveling Self-Reported Signs of Central Sensitization in Breast Cancer Survivors with Upper Limb Pain: Prevalence Rate and Contributing Factors</atitle><jtitle>Pain physician</jtitle><addtitle>Pain Physician</addtitle><date>2018-05-01</date><risdate>2018</risdate><volume>21</volume><issue>3</issue><spage>E247</spage><epage>E256</epage><pages>E247-E256</pages><issn>1533-3159</issn><eissn>2150-1149</eissn><abstract>Hypersensitivity of the central nervous system to environmental and chemical stimuli is a clinical feature of central sensitization mechanisms that can be assessed with the central sensitization inventory (CSI). The aim was to determine prevalence rate of this feature and explore the treatment-, patient-, pain-, and psychosocial-related variables associated with the degree of self-reported signs of central sensitization, assessed with the CSI (0-100), in breast cancer survivors at long-term. Cross-sectional study. University Hospitals, Leuven, Belgium. One hundred and forty-six women with persistent pain, more than one year after breast cancer surgery, were included. The following factors were analyzed by bivariable and multivariable analysis: 1) treatment-related variables (type of surgery, levels of lymph node dissected, radiotherapy, chemotherapy, hormone therapy, and trastuzumab); 2) patient's related variables (age and body mass index); 3) pain-related variables (pain intensity, pain quality, primary hyperalgesia, and index of widespread pain); and 4) psychosocial variables (the degree of pain catastrophizing and vigilance and awareness to pain). The dependent variable was degree of central sensitization measured with the CSI. Additionally, a stepwise regression was performed. Fifty-five (38%) patients reported signs of central sensitization measured with the CSI (i.e., &gt; 40/100). From multivariable analysis, it appears that more severe pain quality and higher levels of pain catastrophizing contribute to a higher degree of central sensitization. The stepwise regression revealed that up to 24% of variance of the CSI can be explained by these factors. A selection bias may be present since patients were all recruited from a larger cohort participating in clinical trials on the effectiveness of physical therapy after breast cancer treatment. Signs of central sensitization cannot be neglected in breast cancer survivors at long term. More severe pain quality and pain catastrophizing contribute to higher levels of central sensitization in this population. Breast neoplasm, pain, central sensitization mechanisms, central sensitization inventory.</abstract><cop>United States</cop><pub>American Society of Interventional Pain Physician</pub><pmid>29871380</pmid><doi>10.36076/ppj.2018.3.e247</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1533-3159
ispartof Pain physician, 2018-05, Vol.21 (3), p.E247-E256
issn 1533-3159
2150-1149
language eng
recordid cdi_proquest_miscellaneous_2051069640
source EZB-FREE-00999 freely available EZB journals
subjects Breast cancer
Cancer therapies
Hyperalgesia
Monoclonal antibodies
Pain
Targeted cancer therapy
Variables
title Unraveling Self-Reported Signs of Central Sensitization in Breast Cancer Survivors with Upper Limb Pain: Prevalence Rate and Contributing Factors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A40%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Unraveling%20Self-Reported%20Signs%20of%20Central%20Sensitization%20in%20Breast%20Cancer%20Survivors%20with%20Upper%20Limb%20Pain:%20Prevalence%20Rate%20and%20Contributing%20Factors&rft.jtitle=Pain%20physician&rft.au=De%20Groef,%20An&rft.date=2018-05-01&rft.volume=21&rft.issue=3&rft.spage=E247&rft.epage=E256&rft.pages=E247-E256&rft.issn=1533-3159&rft.eissn=2150-1149&rft_id=info:doi/10.36076/ppj.2018.3.e247&rft_dat=%3Cproquest_cross%3E2656012850%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2656012850&rft_id=info:pmid/29871380&rfr_iscdi=true